Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMMU $2.20 0.3800 +20.88%
SCLN $8.76 0.6500 +8.01%
VBLT $3.39 0.2300 +7.28%
PVCT $0.52 0.0298 +6.11%
SNSS $0.79 0.0250 +3.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KITE $41.47 -5.7200 -12.12%
OHRP $3.16 -0.3700 -10.48%
PBYI $39.72 -4.2600 -9.69%
CRIS $1.42 -0.1500 -9.55%
ATRA $17.16 -1.6800 -8.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Lynparza™ (olaparib) Granted Breakthrough Therapy Designation by US FDA for Treatment of BRCA1/2 or ATM Gene Mutated Metastatic Castration Resistant Prostate Cancer

(PipelineReview.com) Jan 28, 2016 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza™ (olaparib), for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide).
read article 



Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy

(CNNMoney) Jan 28, 2016 - AbbVie announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the investigational agent venetoclax in combination with hypomethylating agents (HMAs) for the treatment of patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy).
read article 



CAR-T Cell Therapy Can Induce Remission In Reoccurring Blood Cancers After Stem Cell Transplantation Without Causing Graft-vs.-Host Disease

(JTCC) Jan 27, 2016 - A study co-authored by researchers from the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and the National Institutes of Health (NIH) demonstrates that chimeric antigen receptor T-cell (CAR-T) therapy can induce remission of certain blood cancers that may progress after a patient receives stem cell transplantation, while reducing the risk of a potentially fatal post-transplant complication known as graft-versus-host disease (GVHD).
read press release 



FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

(FibroGen) Jan 27, 2016 - FibroGen, Inc. today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and nab-paclitaxel (chemotherapy) compared to those chemotherapy agents alone for the treatment of patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) who have failed resection scoring and are characterized as inoperable.
read corporate press release 



Basic Research Led to First FDA-Approved Immunotherapy for Pediatric Cancer

(Children's Hospital Los Angeles) Jan 27, 2016 - The Children's Oncology Group conducted a randomized, phase 3 trial of dinutuximab and found that children treated with the monoclonal antibody had improved event-free survival and improved overall survival compared to patients who did not receive the immunotherapy.
read press release 



Broad Genetic Testing for Childhood Cancer Patients Can Pinpoint Cancer Causes and Identify Potential Treatments

(Baylor College of Medicine) Jan 28, 2016 - Combined whole exome tumor and blood sequencing in pediatric cancer patients revealed mutations that could help explain the cause of cancer or have the potential to impact clinical cancer care in 40 percent of patients in a study led by researchers from Baylor College of Medicine and Texas Children's Cancer Center.
read press release 



UPMC-Developed Test Rapidly, Accurately Profiles Genetics and Treatment of Brain Tumors

(UPMC) Jan 27, 2016 - Brain tumors can be rapidly and accurately profiled with a next-generation, gene-sequencing test developed at UPMC and the University of Pittsburgh School of Medicine.
read press release 



Researchers Mine the Epigenome to Identify Likely Origins of Childhood Brain Tumor Subtype

(St. Jude Children's) Jan 27, 2016 - An international research team led by a St. Jude Children's Research Hospital scientist mined the epigenome to discover the likely cell of origin for Group 4 medulloblastoma, a key step in developing targeted therapies.
read press release 



Multi-Center Study Reveals Unique Subtypes of Most Common Malignant Brain Cancer

(MD Anderson) Jan 28, 2016 - An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.
read press release 



Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data

(NCCN) Jan 27, 2016 - Thirty-two researchers from 14 institutions joined forces to identify personalized treatment options for a patient with metastatic triple-negative breast cancer.
read press release 



Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

(Yahoo! Finance) Jan 28, 2016 - Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has determined the company's New Drug Application (NDA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy to be sufficiently complete to permit a substantive review.
read article 



CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early

(Bristol-Myers Squibb) Jan 28, 2016 - Opdivo study demonstrates superior overall survival compared to therapy of investigator’s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck.
read corporate press release 



Incyte Stops Tests on Jakafi to Treat Colorectal Cancer

(Reuters) Jan 27, 2016 - Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination treatment after it failed to prove to be sufficiently effective to treat metastatic colorectal cancer.
read article 



US Breakthrough Status for AstraZeneca, AbbVie Drugs

(PharmaTimes [UK]) Jan 28, 2016 - AstraZeneca’s Lynparza has picked up a breakthrough designation in the US as a monotherapy for certain forms of prostate cancer.
read article 



Why Donald Trump Would Have The Same Problems As Democrats On Medicare Drug Prices

(STAT) Jan 26, 2016 - Donald Trump stunned the health care world Monday night with his call for Medicare to negotiate drug prices — an idea that’s straight out of Hillary Clinton’s and Bernie Sanders playbooks, and one that other Republicans won’t touch.
read article 



US Insurers Dragging Feet On Covering New Drugs, Novartis Says

(Reuters) Jan 27, 2016 - Getting U.S. government and commercial insurers to cover new medicines can now take longer than in Europe, Swiss drugmaker Novartis said on Wednesday, blaming U.S. delays for weaker than expected sales of a key heart failure treatment.
read article 



NICE Backs Five Cancer Drugs, Spurns Cyramza

(BioCentury) Jan 26, 2016 - The U.K.'s NICE recommended a quintet of cancer drugs, including reversing a prior decision on Farydak panobinostat from Novartis AG; however, the agency snubbed stomach cancer compound Cyramza ramucirumab from Eli Lilly and Co.
read article 



Appalachia Continues to Have Higher Cancer Incidence Rates Than the Rest of the United States but Gap is Narrowing

(AACR) Jan 27, 2016 - Men and women in Appalachia continue to have higher cancer incidence rates compared with those in the rest of the United States regardless of race or location.
read press release 



AG Calls On Gilead To Lower Price Of Hepatitis C Medicines

(Boston Globe) Jan 27, 2016 - State Attorney General Maura Healey is warning Gilead Sciences Inc. it faces possible legal action unless it lowers the price of two popular hepatitis C medicines.
read article (free registration required) 



Task Force: Doctors Should Screen All Adults For Depression

(USA Today) Jan 26, 2016 - Primary care doctors should screen all adults for depression, an expert panel recommended Tuesday.
read article 



ASCO Publishes Core Curriculum for Cancer Survivorship Education

(ASCO in Action) Jan 26, 2016 - On January 26, the Journal of Oncology Practice (JOP) published an “ASCO Core Curriculum for Cancer Survivorship Education,” a set of recommended content areas and core competencies to be used to guide the education and training of physicians and other allied health professionals in addressing the needs of the growing number of cancer survivors.
read article 



Cancer Riddle, Solved

(University of Iowa/Iowa Now) Jan 25, 2016 - University of Iowa researchers reveal how cancer cells form tumors.
read article 



Home or Away? Award to Study Post-chemo Recovery for Children with Leukemia

(CHOP) Jan 27, 2016 - After children with leukemia receive a course of chemotherapy at a hospital, are they better off remaining in the hospital, or going home with their families?
read article 



ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms

(4-traders) Jan 27, 2016 - ImmunoCellular Therapeutics, Ltd. today announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore.
read article 



ONO PHARMACEUTICAL Selects Medidata to Power Clinical Trials Exploring Additional Cancer Indications for Immunotherapy Drug OPDIVO® (nivolumab)

(TheStreet) Jan 26, 2016 - Japan-based pharma deploys Medidata Rave® to capture, manage and report patient data for clinical trials testing Opdivo against broad range of cancers.
read article